HHS Envisions Drug Price Arbitration For Part D
This article was originally published in The Pink Sheet Daily
Approaches for HHS to become involved in drug price negotiations between Medicare Part D plan sponsors and manufacturers were outlined by HHS Assistant Secretary for Planning and Evaluation Richard Frank at a policy conference, although current law would need to be revised to allow it.
You may also be interested in...
President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.
Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.